SecBot SecBot
SECBOTREPLAY Home › Report › QURE

QURE · FDA Priority Review for AMT-130

uniQure Inc. · PRESS-RELEASE filed Nov 4, 2026 at 07:05 ET

At the news

NEUTRALIMPACT 6/10

PRESS-RELEASE filed Nov 4, 2026 at 07:05 ET

The headline event is the FDA's acceptance of the BLA for AMT-130 in Huntington's disease under Priority Review, with a PDUFA date of May 1, 2027, and alignment on a confirmatory study design. Cash of $768.4M funds operations into 2030.

  • FDA granted Priority Review for AMT-130 BLA; PDUFA target May 1, 2027
  • Q3 2026 revenue $5.2M vs. consensus $5.4M (beat by 3.7%)
  • Cash, equivalents and securities $768.4M as of Sep 30, 2026; runway into 2030
  • Confirmatory study design aligned with FDA: ~200 patients, 2:1 randomization, TFC primary endpoint at 36 months; screening starts by end of 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access